In patients with macular edema resulting from RVO , there was no short-term clinically significant benefit from monthly injections of @-mg versus @-mg ranibizumab injections and no long-term benefit in BCVA , resolution of edema , or number of ranibizumab injections obtained by addition of laser treatment to ranibizumab .